A randomized controlled trial conducted by Eli Lilly evaluated the efficacy and durability of weight loss with tirzepatide in patients with obesity. The study assessed both the weight reduction phase and the weight maintenance phase across different dosing strategies of their dual GLP-1/GIP receptor agonists. Participants who achieved initial weight loss with active treatment were then randomized to continue treatment or transition to placebo during the maintenance phase, allowing researchers to quantify the contribution of ongoing pharmacotherapy to sustained weight reduction versus weight regain.
Key findings demonstrated that tirzepatide treatment produced clinically significant weight loss in the initial phase, with participants maintaining substantially lower body weight when continuing active treatment during the maintenance period compared to those who transitioned to placebo. The magnitude of weight regain in the placebo group during maintenance was substantial, indicating that weight loss achieved with tirzepatide requires continued pharmacotherapy for durability. The trial included evaluation across lower doses, providing prescribers with data on dose-response relationships and the minimum effective dosing strategies.
For clinical practice, these findings reinforce that obesity management with tirzepatide represents a chronic disease model requiring ongoing pharmacotherapy rather than a time-limited intervention. The rapid weight regain observed upon treatment discontinuation underscores the importance of patient selection, treatment initiation with realistic expectations about disease chronicity, and planned continuation strategies when therapy is effective. Prescribers should counsel patients that interrupting or discontinuing tirzepatide leads to predictable weight recurrence, informing shared decision-making discussions about long-term treatment commitment and adherence expectations.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is a GLP-1 medication and how does it work for weight loss?
- Are GLP-1 drugs like Zepbound and Mounjaro the same medication?
- How much weight can I expect to lose with GLP-1 therapy?
- Will I regain the weight if I stop taking GLP-1 medication?
- What are the common side effects of GLP-1 medications?
- How long does it take to see weight loss results with GLP-1 therapy?
- Is GLP-1 therapy safe for long-term use?
- Can I use GLP-1 medication if I have type 2 diabetes?
- Do I need to diet and exercise while taking GLP-1 medication?
- How often do I need to take GLP-1 injections?
FAQ
What is a GLP-1 medication and how does it work for weight loss?
GLP-1 medications are injectable drugs that mimic a hormone your body naturally makes to regulate blood sugar and appetite. They work by slowing digestion, helping you feel fuller longer, and reducing cravings, which leads to eating less and losing weight.
Are GLP-1 drugs like Zepbound and Mounjaro the same medication?
Zepbound and Mounjaro contain the same active ingredient (tirzepatide) but are approved for different uses. Mounjaro is approved for type 2 diabetes, while Zepbound is specifically approved for chronic weight management in people with obesity or overweight with weight-related conditions.
How much weight can I expect to lose with GLP-1 therapy?
Clinical trials show that patients on GLP-1 medications lose an average of 15 to 22 percent of their body weight over one year, though individual results vary based on your starting weight, lifestyle changes, and how your body responds to the medication.
Will I regain the weight if I stop taking GLP-1 medication?
Studies indicate that many people do regain some weight after stopping the medication, which is why it is often considered a long-term treatment similar to medications for high blood pressure or diabetes that require ongoing use.
What are the common side effects of GLP-1 medications?
The most common side effects include nausea, vomiting, diarrhea, and constipation, especially when starting the medication or increasing the dose. These side effects often improve over time as your body adjusts to the medication.
How long does it take to see weight loss results with GLP-1 therapy?
Most people begin to notice weight loss within the first 2 to 4 weeks of starting the medication, with the most significant losses occurring between months 2 and 6 of treatment.
Is GLP-1 therapy safe for long-term use?
Current clinical evidence supports the safety of GLP-1 medications for long-term use in people with obesity or type 2 diabetes, though your doctor will monitor you regularly for any side effects or changes in your health.
Can I use GLP-1 medication if I have type 2 diabetes?
Yes, GLP-1 medications are approved for type 2 diabetes and actually provide benefits beyond weight loss by helping to improve blood sugar control and reduce the risk of heart disease and kidney problems.
Do I need to diet and exercise while taking GLP-1 medication?
Yes, combining GLP-1 medication with a healthy diet and regular physical activity produces better weight loss results than medication alone and helps you maintain your weight loss long-term.
How often do I need to take GLP-1 injections?
Most GLP-1 medications are given as once-weekly injections that you can administer yourself at home, making them convenient for long-term treatment compared to daily medications.
